Featured News
June 03, 2024
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
Our Commitment to Responsibility
Corporate responsibility has always played a central role in our business and has proven even more critical in recent years as we navigated pressing public health and societal issues– a dynamic global pandemic, systemic racism in the U.S. and around the world, and a worsening climate change crisis. Guided by our purpose and values, we took actions to respond to these critical issues, while sharpening our focus on scientific and business excellence in our efforts to help people living with complex and difficult-to-treat diseases. Our most recent Corporate Responsibility Report expounds on these efforts.
Our Stories
Each endeavor at Alkermes starts with collaboration and our shared commitment to make a difference for patients and our communities. These stories – which highlight our people, science and innovation, and leadership perspectives – showcase just a subset of what makes us proud to be part of Alkermes. Visit our full gallery of stories by clicking on the link below.
Alkermes in Action 2024
Now in its 16th year, Alkermes’ employees got to work volunteering for Alkermes in Action.
Sharing Reflections on Pride Month
Our Pride@Work Executive Sponsors are committed to supporting the LGBTQ+ community.
Celebrating our 2024 Interns
Steve Schiavo reflects on the contributions of our 2024 intern class as we mark National Intern Day.
Media Resources
Company Description
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, headquartered in Ireland with U.S. locations in Massachusetts and Ohio, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.
Follow us on our social channels
